Inotuzumab (powder)
Based on 1 publication(s) in Google Scholar
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1660159-36-3
- Peso molecular:146.48 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Inotuzumab (powder)
More
Actividad biológica
Descripciòn
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Inotuzumab ozogamicin (100, 1000 ng/mL, 6 h) induces apoptosis in acute lymphoblastic leukemia (ALL) cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Inotuzumab (0.27, 3.2 mg/kg, i.p., a single dose for 400 h) (powder) inhibits tumor growth in mouse xenograft models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse xenograft models[4].
-
Dosage:0.27, 3.2 mg/kg
-
Administration:i.p., a single dose for 400 h
-
Result:Decreased the tumor volume in mouse xenograft models.
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 1660159-36-3
-
Peso molecular 146.48 kDa
-
SMILES
[Inotuzumab (powder)]
-
Synonyms
Humanized Anti-CD22 Recombinant Antibody (powder)
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
Referencias
[1]. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. [Content Brief]
[2]. Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. [Content Brief]
[3]. Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. [Content Brief]
[4]. Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Inotuzumab (powder) Related Classifications
HY-P99264A Related Classifications
Powered by Bioz